FDA Drug recall D-1250-2014
XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
- FDA Drug
- Class I
- terminated
- Published 2014-04-30
On 2014-04-30 the FDA classified a Class I recall of XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box by Dolphin Intertrade, citing marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products una….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1250-2014 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2013-05-20 |
| Published | 2014-04-30 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Dolphin Intertrade |
| Distribution | US |
Product
XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
Reason
Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Identifiers
| code_info | All Lots |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1250-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.